Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Orosur Mining consultant exercises stock options

(Sharecast News) - Orosur Mining announced the issue of 83,333 new shares on Tuesday, following the exercise of stock options by a company consultant at an exercise price of six Canadian cents per share. The AIM-traded firm said the newly-issued shares represented 0.03% of its current issued share capital.

Application had been made for the new shares to be admitted to trading on AIM, with admission and dealings expected to start at 0800 BST on or around 25 April.

The new shares would rank equally with existing shares in issue.

No directors or executives of the company were involved in the option exercise, Orosur confirmed.

Following admission, its total issued share capital would consist of 312,523,237 common shares, with 4,961,668 options outstanding.

At 0943 BST, shares in Orosur Mining were down 0.19% at 13.08p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

BioNTech to invest up to £1bn in UK R&D expansion
(Sharecast News) - BioNTech announced on Tuesday that it will invest up to £1bn over the next decade to expand its research and development footprint in the UK, backed by a government grant of up to £129m.
Image Scan warns on profits, shares slump
(Sharecast News) - Shares in Image Scan tumbled on Tuesday, after the X-ray screening specialist warned on profits following a "disappointing" first half.
Mosman Oil & Gas in talks to sell Billy Goat rights
(Sharecast News) - Mosman Oil and Gas said on Tuesday that it has been in talks with a local helium business interested in buying the first well and associated contractual rights of the Billy Goat area of mutual interest (AMI) lease at its Vecta Project in Colorado.
RBC Capital ups price target on Hikma
(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.